Dedifferentiated Chondrosarcoma
specificAn aggressive morphologic variant of chondrosarcoma. It is composed of a low grade chondrosarcoma and a high grade non-cartilagenous sarcomatous component. Due to the aggressive nature of the disease, its prognosis is poor.
8
Centers
8
Active Trials
—
Cancer Funding
Top Centers for Dedifferentiated Chondrosarcoma(8)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 56.2 |
| 2 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 56.2 |
| 3 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 56.2 |
| 4 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 56.2 |
| 5 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 56.2 |
| 6 | USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive Active Research Program | 56.2 |
| 7 | UF Health Cancer InstituteGainesville, FL NCI Clinical Active Research Program | 56.2 |
| 8 | Boston University Cancer CenterBoston, MA Active Research Program | 56.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →